Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer
The Canazawa classification differentiated the prognosis of mCSPC patients more clearly. A PSA reduction rate of <95% at 12 w after starting ADT in low-risk, low-volume patients of all risk classifications was significantly shorter than the TTCR. We propose a new treatment strategy, in which patients with low-risk mCSPC are treated with ADT and switched to ARSIs based on the rate of PSA reduction at 12 w.
Authors
- Kouji Izumi
- Hiroaki Iwamoto (ORCID: https://orcid.org/0000-0003-3599-2217)
- Takahiro Nohara (ORCID: https://orcid.org/0000-0001-9792-2068)
- Shohei Kawaguchi (ORCID: https://orcid.org/0000-0001-6847-9861)
- Renato Naito
- Atsushi Mizokami (ORCID: https://orcid.org/0000-0002-5643-2182)
- Hiroshi Yaegashi (ORCID: https://orcid.org/0000-0003-3188-8834)
- Tomohiro Hori (ORCID: https://orcid.org/0000-0002-0841-3382)
- Kazuyoshi Shigehara (ORCID: https://orcid.org/0000-0002-2118-9135)
- Ryunosuke Nakagawa (ORCID: https://orcid.org/0000-0002-2503-8908)
- Tomoyuki Makino
- Hiroshi Kano (ORCID: https://orcid.org/0000-0002-3543-1236)
Institutions
- Kanazawa University (JP)
Publication Details
- Journal
- Cancers
- Published
- 2024-09-19
- DOI
- https://doi.org/10.3390/cancers16183198
- Citations
- 5
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09